Table 2.
Trends in time from diagnosis to treatment in female cancer patients with different stages
| Variables | No. (%) of patients | P* | ||
|---|---|---|---|---|
| < 1 month (immediate treatment) | 1–2 months (intermediate delay) | 3–6 months (long delay) | ||
| NSCLC | ||||
| Stage I | 2896 (31.1) | 5104 (54.7) | 1321 (14.2) | < 0.001 |
| Stage II | 764 (23.2) | 2056 (62.4) | 476 (14.4) | |
| IBC | ||||
| Stage I | 23,424 (23.7) | 70,132 (70.8) | 5470 (5.5) | < 0.001 |
| Stage II | 16,576 (24.7) | 46,367 (69.2) | 4082 (6.1) | |
| DTC | ||||
| Stage I | 19,172 (66.6) | 7994 (27.8) | 1610 (5.6) | 0.043 |
| Stage II | 1589 (68.5) | 590 (25.4) | 141 (6.1) | |
| Colorectal cancer | ||||
| Stage I | 6791 (60.5) | 4099 (36.5) | 339 (3.0) | < 0.001 |
| Stage II | 6491 (52.7) | 5474 (44.4) | 356 (2.9) | |
| Cervical cancer | ||||
| Stage I | 3369 (51.3) | 2652 (40.4) | 545 (8.3) | < 0.001 |
| Stage II | 425 (23.9) | 1141 (64.1) | 214 (12.0) | |
The tumor stage refers to the TNM stage classification in the 7th edition
NSCLC non-small cell lung cancer, IBC infiltrating breast cancer, DTC differentiated thyroid carcinoma
Bold values indicate statistical significance (p < 0.05)
*Pearson’s Chi-squared test